CAPLIPOINTCaplin Point Laboratories Ltd.

₹2015.2-2.02%

Market Cap

₹15,623.82 Cr

Stock P/E

27.65

ROCE

26.22%

ROE

21.72%

Book Value

₹382.44

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Strong liquidity and no debt to fund growth.
•
Caplin Steriles USA profitability and product rollout progressing well.

NEGATIVES

•
Geopolitical protectionism risk and potential impact on growth.
•
CAPEX timeline shifted, delaying on-ground expansion.

Peers Summary

Sector Leader

Caplin Point Laboratories Ltd. displays strong growth and profitability metrics compared to its peers, with the highest revenue growth rates and solid margins, positioning it as a sector leader in the pharmaceuticals and drugs industry. However, it also has a high valuation, which may temper its attractiveness for value-seeking investors.

Key Points

• Caplin Point has the highest revenue growth (YoY: 15.5%, 3-Year: 15.14%) among peers.
• Dr. Reddy's Laboratories boasts the highest ROE and ROCE at 21.76% and 26.86%, respectively.
• Cipla Ltd. has the lowest PE ratio at 23.73, making it an attractive value pick.
• Divi's Laboratories has the lowest revenue growth YoY at 1% and a declining EPS over 3 years.

Top Performers

Caplin Point Laboratories Ltd.

Highest revenue growth rates and strong profitability metrics.

Dr. Reddy's Laboratories Ltd.

Strong ROE and ROCE, indicating effective use of equity and capital.

Cipla Ltd.

Lowest PE ratio, suggesting it may be undervalued relative to earnings.

Explore

Watchlists

Command Palette